Supernus to Present at March Cowen Conference
February 18 2015 - 5:00PM
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty
pharmaceutical company focused on developing and commercializing
products for the treatment of central nervous system diseases,
today announced that the Company's management will present an
overview of the Company and host investor meetings at the Cowen and
Company Healthcare Conference.
Presentation Date: Wednesday, March 4
Time: 8:40 AM ET Place: The Boston Marriott Copley Place Hotel,
Boston, MA
Investors interested in arranging a meeting with the Company's
management during this conference should contact the conference
coordinator.
A live webcast of the presentation can be accessed by visiting
"Events & Presentations" in the Investors section on the
Company's website at www.supernus.com. An archived replay of the
webcast will be available for 60 days on the Company's website
after the conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system, or CNS, diseases. The Company
has two marketed products for epilepsy, Oxtellar XR®
(extended-release oxcarbazepine) and Trokendi XR® (extended-release
topiramate). The Company is also developing several product
candidates to address large market opportunities in psychiatry.
These product candidates include SPN-810 for the treatment of
impulsive aggression in patients with ADHD in conjunction with
standard ADHD treatment and SPN-812 for ADHD.
CONTACT: Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
Or
Investor Contact:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Apr 2023 to Apr 2024